Literature DB >> 30091381

Novel differences in gene expression and functional capabilities of myofibroblast populations in idiopathic pulmonary fibrosis.

Sinead M Walsh1,2, Julie C Worrell1, Aurelie Fabre3, Boris Hinz4, Rosemary Kane1, Michael P Keane1,2.   

Abstract

Idiopathic pulmonary fibrosis (IPF), a chronic progressive interstitial pneumonia, is characterized by excessive fibroproliferation. Key effector cells in IPF are myofibroblasts that are recruited from three potential sources: resident fibroblasts, fibrocytes, and epithelial cells. We hypothesized that IPF myofibroblasts from different sources display unique gene expression differences and distinct functional characteristics. Primary human pulmonary fibroblasts (normal and IPF), fibrocytes, and epithelial cells were activated using the profibrotic factors TGF-β and TNF-α. The resulting myofibroblasts were characterized using cell proliferation, soluble collagen, and contractility assays, ELISA, and human fibrosis PCR arrays. Genes of significance in human whole lung were validated by immunohistochemistry on human lung sections. Fibroblast-derived myofibroblasts exhibited the greatest increase in expression of profibrotic genes and genes involved in extracellular matrix remodeling and signal transduction. Functional studies demonstrated that myofibroblasts derived from fibrocytes expressed mostly soluble collagen and chemokine (C-C) motif ligand (CCL) 18 but were the least proliferative of the myofibroblast progeny. Activated IPF fibroblasts displayed the highest levels of contractility and CCL2 production. This study identified novel differences in gene expression and functional characteristics of different myofibroblast populations. Further investigation into the myofibroblast phenotype may lead to potential therapeutic targets in future IPF research.

Entities:  

Keywords:  MMP9; fibrosis; gremlin; myofibroblast; thrombospondin

Mesh:

Substances:

Year:  2018        PMID: 30091381     DOI: 10.1152/ajplung.00543.2017

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  10 in total

1.  Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.

Authors:  Eleanor Valenzi; Melissa Bulik; Tracy Tabib; Christina Morse; John Sembrat; Humberto Trejo Bittar; Mauricio Rojas; Robert Lafyatis
Journal:  Ann Rheum Dis       Date:  2019-08-12       Impact factor: 19.103

Review 2.  Involvement of 4-hydroxy-2-nonenal in the pathogenesis of pulmonary fibrosis.

Authors:  Edilburga Reyes-Jiménez; Alma Aurora Ramírez-Hernández; Jovito Cesar Santos-Álvarez; Juan Manuel Velázquez-Enríquez; Socorro Pina-Canseco; Rafael Baltiérrez-Hoyos; Verónica Rocío Vásquez-Garzón
Journal:  Mol Cell Biochem       Date:  2021-08-31       Impact factor: 3.396

3.  Anti-Inflammatory and Anti-Fibrotic Effect of Immortalized Mesenchymal-Stem-Cell-Derived Conditioned Medium on Human Lung Myofibroblasts and Epithelial Cells.

Authors:  Eirini Filidou; Leonidas Kandilogiannakis; Gesthimani Tarapatzi; Michail Spathakis; Paschalis Steiropoulos; Dimitrios Mikroulis; Konstantinos Arvanitidis; Vasilis Paspaliaris; George Kolios
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

4.  Fibroblastic and bone marrow-derived cellularity in the corneal stroma.

Authors:  Steven E Wilson; Lycia Pedral Sampaio; Thomas Michael Shiju; Rodrigo Carlos de Oliveira
Journal:  Exp Eye Res       Date:  2020-10-14       Impact factor: 3.467

5.  Laser capture microdissection coupled mass spectrometry (LCM-MS) for spatially resolved analysis of formalin-fixed and stained human lung tissues.

Authors:  Jeremy A Herrera; Venkatesh Mallikarjun; Silvia Rosini; Maria Angeles Montero; Craig Lawless; Stacey Warwood; Ronan O'Cualain; David Knight; Martin A Schwartz; Joe Swift
Journal:  Clin Proteomics       Date:  2020-06-17       Impact factor: 3.988

6.  Latent Transforming Growth Factor-β Binding Protein-2 Regulates Lung Fibroblast-to-Myofibroblast Differentiation in Pulmonary Fibrosis via NF-κB Signaling.

Authors:  Menglin Zou; Jingfeng Zou; Xingxing Hu; Weishuai Zheng; Mingyang Zhang; Zhenshun Cheng
Journal:  Front Pharmacol       Date:  2021-12-24       Impact factor: 5.810

7.  A novel prognostic signature for idiopathic pulmonary fibrosis based on five-immune-related genes.

Authors:  Lingxiao Qiu; Gencheng Gong; Wenjuan Wu; Nana Li; Zhaonan Li; Shanshan Chen; Ping Li; Tengfei Chen; Huasi Zhao; Chunling Hu; Zeming Fang; Yan Wang; Hongping Liu; Panpan Cui; Guojun Zhang
Journal:  Ann Transl Med       Date:  2021-10

8.  Transcriptomic and Epigenetic Profiling of Fibroblasts in Idiopathic Pulmonary Fibrosis.

Authors:  Ankit Hanmandlu; Lisha Zhu; Tinne C J Mertens; Scott Collum; Weizhen Bi; Feng Xiong; Ruoyu Wang; Rajarajan T Amirthalingam; Dewei Ren; Leng Han; Soma S S K Jyothula; Wenbo Li; W Jim Zheng; Harry Karmouty-Quintana
Journal:  Am J Respir Cell Mol Biol       Date:  2022-01       Impact factor: 7.748

9.  Pulmonary fibrosis: something old, something new…still waiting for a breakthrough.

Authors:  Carol Feghali-Bostwick
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-08-05       Impact factor: 5.464

10.  Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis.

Authors:  Laura Duffy; John Henderson; Max Brown; Stefan Pryzborski; Nicola Fullard; Lena Summa; Jorg H W Distler; Richard Stratton; Steven O'Reilly
Journal:  Front Cell Dev Biol       Date:  2021-06-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.